Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium

Clinical Infectious Diseases

Volumn 35, Issue 10, 2002, Pages 1269-1272

  Pai, Manjunath P ^a   Rodvold, Keith A ^b,c   Schreckenberger, Paul C ^b   Gonzales, Ronald D ^c   Petrolatti, Jennifer M ^d   Quinn, John P ^c,e  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d JESSE BROWN VA MEDICAL CENTER   (United States)

^e Jr Hospital of Cook County   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; OXAZOLIDINONE DERIVATIVE; POSIZOLID; UNCLASSIFIED DRUG; VANCOMYCIN;

ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EXPOSURE; ENTEROCOCCUS FAECIUM; FEMALE; HUMAN; INFECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR;

ACETAMIDES; ANTI-BACTERIAL AGENTS; ENTEROCOCCUS FAECIUM; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OXAZOLIDINONES; RISK FACTORS; VANCOMYCIN RESISTANCE;

EID: 0037111554     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/344177     Document Type: Article

References (13)

1. Martone WJ. Spread of vancomycin-resistant enterococci: Why did it happen in the United States? Infect Control Hosp Epidemiol 1998; 19:539-45.
2. Linezolid (Zyvox) [Package Insert]. Peapack, NJ: Pharmacia & Upjohn Company, 2001.
3. Zurenko G, Todd WM, Hafkin BA. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid [abstract 848]. In: Programs and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology Press, 1999:118.
4. Lee JC, Zurenko GE, Shinabarger DL, Cammarata SK. Factors which may influence development of clinical resistance to linezolid in enterococcal species [abstract 531]. In: Programs and Abstracts of the 39th Annual Meeting of the Infectious Diseases Society of America (San Francisco). Alexandria, VA: Infectious Diseases Society of America, 2001:130.
5. Gonzales RD, Schreckenberger PC, Graham MB, et al. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001; 357:1179.
6. Zurenko GE, Yagi BH, Schadt JW, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40:839-45.
7. Prystowsky J, Siddiqui F, Chosay J, et al. Resistance to linezolid: Characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001; 45:2154-6.
8. Kloss P, Xiong L, Shinabarger D, Mankin AS. Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J Mol Biol 1999; 294:93-101.
9. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358:207-8.
10. Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. JAMA 2001; 285:1291.
11. Hererro IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant vancomycin-resistant Enterococcus faecium. N Engl J Med 2002; 346:867-8.
12. Linden PK, Moellering RC, Wood CA, et al. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis 2001; 33:1816-23.
13. Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 1999; 44:251-61.